The clinical logic behind the trial rests on a fundamental tension in pediatric cardiology. Warfarin, a vitamin K antagonist, works by interfering with the liver’s production of several clotting factors, and its effect is measured through the international normalized ratio, or INR, a laboratory value that must be kept within a narrow therapeutic window. Too low, and clots can form on the replacement valve; too high, and bleeding becomes a serious risk. In children, this balancing act is complicated by growth spurts, dietary variability, intercurrent illness, and drug interactions, all of which can send INR values swinging unpredictably. Frequent blood draws, often from veins that are small and difficult to access, add a physical and emotional burden that families know all too well. Rivaroxaban, by contrast, directly inhibits Factor Xa, a key enzyme in the coagulation cascade, and produces a more predictable anticoagulant effect at fixed doses without routine monitoring. Pediatric dosing guidelines, such as those developed at the Mayo Clinic, have made it increasingly feasible to use the drug in younger populations, but its role specifically after pulmonary valve replacement had never been formally tested.

To fill that gap, the research team led by Mohammad Reza Sabri and colleagues at the Pediatric Cardiovascular Research Center of Isfahan University of Medical Sciences designed a randomized, double-blind clinical trial. They enrolled 44 patients over the age of five, with the youngest participant being nine years old, all of whom had undergone pulmonary valve replacement at the referral center. The investigators deliberately excluded patients with a history of thrombosis, paradoxical embolism, or reduced ejection fraction, as well as anyone with hypersensitivity to the study medications, to create a well-defined study population. Participants were randomly assigned to receive either warfarin at a dose of 0.1 to 0.3 milligrams per kilogram per day, adjusted according to INR monitoring, or rivaroxaban dosed according to the Mayo Clinic pediatric guidelines. The trial was registered in the Iranian Registry of Clinical Trials under identifier IRCT20220516054868N2, and the protocol received ethics approval in accordance with the Declaration of Helsinki, with written informed consent obtained from adult participants and from parents or guardians of minors, along with age-appropriate assent from the children themselves.

Follow-up lasted a mean of approximately six months, during which patients were assessed for both thromboembolic complications, such as valve thrombosis, stroke, or pulmonary embolism, and hemorrhagic events, ranging from minor bruising to clinically significant bleeding. Three patients were lost to follow-up, leaving 41 participants in the final analysis: 22 in the warfarin group and 19 in the rivaroxaban group. The baseline characteristics of the two groups were broadly similar, with one notable exception: body weight was significantly higher in the rivaroxaban group, a difference the authors reported with a p value of 0.044. This kind of imbalance is an inherent hazard of small randomized trials, and while it does not undermine the central findings, it is the sort of detail that clinicians reading the study will weigh when interpreting how the results might generalize to their own patients.

The headline efficacy result was unambiguous. Across roughly six months of follow-up, no thromboembolic or cerebrovascular events occurred in either treatment arm. In a trial of this size, the absence of events cannot statistically prove that the two drugs are identical in their protective effect, but it establishes that rivaroxaban kept the replacement valves clot-free in every patient studied, matching warfarin’s performance over the observation period. For a condition in which even a single valve thrombosis can be catastrophic, that finding carries real weight. It also aligns with a broader trend in pediatric hematology and cardiology, where direct oral anticoagulants have been steadily earning a place in the prevention and treatment of venous thromboembolism in children, backed by pharmacokinetic studies and dedicated pediatric trials in other clinical settings.

The safety picture was similarly reassuring, with one instructive exception. A single patient in the warfarin group, representing 4.54 percent of that arm, developed hemoptysis, the coughing up of blood that is always an alarming symptom in a young patient. On investigation, the bleeding was attributed not to the anticoagulant effect itself in a straightforward sense but to an underlying arteriovenous malformation, an abnormal tangle of vessels that can bleed when anticoagulated. When the patient was switched to rivaroxaban, the hemoptysis resolved. The episode illustrates a practical reality of anticoagulation medicine: the drug is only one variable in a complex hemostatic system, and individual anatomy can transform a standard therapy into a hazardous one. It also hints, cautiously, that switching agents may sometimes solve a bleeding problem, though a single case cannot establish that rivaroxaban is inherently safer in such situations.

Where the trial produced its most dramatic statistical separation was in patient satisfaction, measured on a ten-point scale. Patients taking rivaroxaban rated their anticoagulation experience at a mean of 8.26 with a standard deviation of 1.99, while those on warfarin averaged just 5.14 with a standard deviation of 1.09, a difference the authors reported as highly significant with a p value below 0.001. The gap is easy to explain in human terms. Warfarin demands regular blood tests to check INR, careful attention to vitamin K intake from leafy greens, vigilance about interactions with common medications including non-steroidal anti-inflammatory drugs, and dose adjustments that can feel arbitrary and anxiety-inducing. Rivaroxaban requires none of that routine monitoring, freeing adolescents and young adults from the needle sticks and dietary calculations that define life on warfarin. For a population that includes teenagers heading to school, sports, and social lives, the convenience factor is not a luxury; it directly shapes adherence, and poor adherence to anticoagulation is one of the most dangerous failure modes in congenital heart disease care.

The study’s limitations are the familiar companions of small, single-center trials. Forty-one analyzed patients is enough to detect a large difference in satisfaction and to observe the absence of events, but not enough to rule out rare thrombotic complications that might emerge with a frequency of one or two percent. The six-month follow-up window captures the early period after valve replacement, when thrombosis risk is highest, but cannot speak to outcomes over the years and decades that these valves remain in place. The weight imbalance between groups, and the fact that the trial took place at a single tertiary referral center with experienced pediatric cardiac teams, both counsel caution before extrapolating the results universally. The authors themselves frame the findings as support for further evaluation rather than as a definitive practice-changing verdict, and that framing is scientifically appropriate.

Even so, the trial lands at a meaningful moment. Congenital heart disease survivors now outnumber congenital heart disease deaths in much of the world, and the population of adolescents and adults living with replacement pulmonary valves continues to grow. Every one of those patients faces the question of how to anticoagulate safely, and many of them are warfarin patients who endure the monitoring burden for years. Direct oral anticoagulants have already transformed stroke prevention in adult atrial fibrillation and the treatment of venous thromboembolism, but pediatric congenital heart surgery has been a more conservative frontier, partly because the evidence base in children is thin and partly because the anatomy and flow dynamics of repaired hearts differ from the conditions in which the drugs were originally validated. A randomized trial specifically in the pulmonary valve replacement population, however small, chips away at that evidence gap.

For families sitting in a pediatric cardiology clinic weighing anticoagulation options after valve replacement, the practical takeaway is one of cautious optimism rather than immediate change. The Isfahan trial suggests that rivaroxaban, dosed according to established pediatric guidelines, can protect a new pulmonary valve as effectively as warfarin over the crucial first months, with a favorable safety record and a dramatically better day-to-day experience for patients. Larger, longer, and multicenter trials will be needed before guidelines can confidently recommend the newer drug as a default, and individual factors such as valve type, heart anatomy, and bleeding risk will always shape the decision. But the direction of travel is clear: the field is moving toward anticoagulation strategies that respect both the physiology of the growing heart and the lived reality of the young person carrying it, and this study offers some of the first randomized evidence that the newer agents deserve a serious place in that conversation.

Subject of Research: Anticoagulation with rivaroxaban versus warfarin after pediatric pulmonary valve replacement

Article Title: Comparative efficacy and safety of rivaroxaban versus warfarin in patients following pulmonary valve replacement: a randomized controlled trial

Article References: Sabri, M. R., Dehghan, B., Ghasemi, M., Ahmadi, A. R., Ghaderian, M., Mahdavi, C., Nezhad, D. R., Navabfar, N., & Nourmohammadi, H. (2026). Comparative efficacy and safety of rivaroxaban versus warfarin in patients following pulmonary valve replacement: a randomized controlled trial. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07702-9

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07702-9

Keywords: rivaroxaban, warfarin, pulmonary valve replacement, pediatric cardiology, congenital heart disease, anticoagulation, thromboprophylaxis, direct oral anticoagulants, randomized controlled trial, patient satisfaction, thromboembolism, INR monitoring